Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Otsuka Obtains U.S. FDA Fast Track Review For Dry AMD Oral Treatment

This article was originally published in PharmAsia News

Executive Summary

U.S. FDA granted a fast track review of Otsuka's dry age-related macular degeneration oral treatment ACU-4429. Developed by Tokyo-based Otsuka Pharmaceutical and Bothell, WA-based biotech Acucela, ACU-4429 is in Phase II studies in the U.S. Utilizing Accuela proprietary visual cycle modulation technology, the compound is developed to prevent or inhibit the generation of toxic byproducts that can lead to degenerative eye conditions like dry AMD. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts